bHighlights:/b
ul class="group-list punch-points"liThe results of ALEX trial were
presented at the European Lung Cancer Congress (ELCC ) 2018 by Dr. Perol
supporting the use of alectinib in lung cancer./liliAlectinib, a next generation
tyrosine kinase inhibitor found to be the frontline treatment in patients
with ALK-positive non-small-cell lung cancer./liliWhen compared with the standard
crizotinib therapy, alectinib improves the symptoms of ...
bHighlights:/b
ul class="group-list punch-points"liThe results of ALEX trial were
presented at the European Lung Cancer Congress (ELCC ) 2018 by Dr. Perol
supporting the use of alectinib in lung cancer./liliAlectinib, a next generation
tyrosine kinase inhibitor found to be the frontline treatment in patients
with ALK-positive non-small-cell lung cancer./liliWhen compared with the standard
crizotinib therapy, alectinib improves the symptoms of ...